2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 916

Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density
Abstract Number: 2965

Effects of Anti-NGF Strategies in Two Animal Models of Osteoarthritis (OA)
Abstract Number: 2750

Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet’s Disease with Vascular Involvement
Abstract Number: 2836

Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 684

Effects of Current Therapies for Lupus on Disease Activity and Renal Flares
Abstract Number: 2260

Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients
Abstract Number: 2916

Effects of Exercise on Body Composition, Cardiovascular Fitness, Muscle Strength, and Cognition in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial of a Patient-Specific Exercise Programme
Abstract Number: 67

Effects of Exercise on Depressive Symptoms in Adults with Arthritis: A Systematic Review with Meta-Analysis
Abstract Number: 2242

Effects of Intraarticular (IA) Corticosteroid Injections on Bone Markers and Endogenous Cortisol in Patients with Knee Osteoarthritis (OA): A Randomized, Double-Blind, Placebo Controlled Trial
Abstract Number: 1938

Effects of Mesenchymal Stem Cells on Human B Cell Proliferation
Abstract Number: 2915

Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Abstract Number: 1685

Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis
Abstract Number: 2256

Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study
Abstract Number: 2591

Effects of Self-Management Model on the Disease-Related Knowledge, Joint Function and Quality of Life in Patients with Ankylosing Spondylitis
Abstract Number: 1181

Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naïve Patients with Early Active Rheumatoid Arthritis (Duration ≤2 Years): Results of an Exploratory Phase 2 MRI Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].